Novavax

The Cancer Immunotherapy Market report forecasts significant growth by 2029, highlighting advancements in therapies like CAR-T Cells and Checkpoint Inhibitors. It offers insights into market opportunities, key players, and technologies driving the revolution in cancer treatment.

CDC recommends all adults get the 2024-2025 COVID-19 vaccine. Previously vaccinated adults need 1 dose; unvaccinated adults need 1 or 2 doses, depending on the vaccine. Adults 65+ and those with weakened immune systems require 2 doses, 6 months apart, with possible additional doses.

CDC recommends mRNA COVID-19 vaccines for people with psoriasis, despite potential flare-ups, due to their effectiveness against severe infection. Vaccines are safe, even for those on immunosuppressive therapy, though effectiveness may vary. Complete vaccination is advised, with additional doses for immunocompromised individuals.

The FDA granted fast track designation to two combination flu and COVID-19 vaccine candidates for adults 50+; one combines Fluzone High-Dose with Novavax's COVID-19 vaccine, the other uses Flublok paired with the same COVID-19 vaccine. Both aim to reduce health burdens of flu and COVID-19, especially for high-risk groups, and are undergoing phase ½ trials to evaluate safety and immune responses.

A.F., M.E.S., S.R.W., C.M.E., N.R., C.L.G., K.L.K., J.A.G., E.A.H., and M.D.T. disclosed various research grants, advisory board fees, and institutional funding from pharmaceutical companies and NIH/NIAID, indicating potential conflicts of interest relevant to the manuscript's content.

Novavax achieved a $50M milestone payment from Sanofi for its COVID-19 vaccine in children, with potential for up to $300M in additional payments and royalties. The combination vaccines for influenza and COVID-19 received Fast Track designation, and the sale of the Czech Republic manufacturing site strengthens financial position.

Novavax achieved a $50 million milestone in its partnership with Sanofi, advancing its COVID-19 vaccine in children and receiving Fast Track designation for combination vaccine candidates. Additional milestones and royalties are potential, solidifying future partnership models.

Novavax achieved a $50 million milestone in its partnership with Sanofi, advancing its COVID-19 vaccine in children. Sanofi's combination vaccine candidates, including Novavax's vaccine, have received Fast Track designation and are in Phase 1/2 trials, potentially leading to further milestones and royalties for Novavax.

Sanofi's combo vaccine candidates for flu and Covid-19 in people aged 50+ received FDA fast track designation, combining existing vaccines with demonstrated efficacy. Two Phase I/II trials assess immune response and safety, aiming for simpler scheduling and fewer injections.

Novavax initiated a phase III study for its COVID-19-influenza combo and standalone influenza vaccines, targeting adults 65+. Utilizing Matrix-M adjuvant, it aims for FDA accelerated approval, supported by mid-stage study data. Novavax's shares rose 82.7% YTD. Competitors like Pfizer and Moderna are also developing COVID/flu vaccines, with Moderna leading in late-stage development.